NCT03596866 2025-09-12
ALTA-3
Takeda
Phase 3 Completed
Clinical Trials
12 trialsNCT02075840 2025-07-25
ALEX
Hoffmann-La Roche
Phase 3 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT03546894 2024-07-15
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
Takeda
Completed
NCT06339554 2024-04-01
TOSS-ALK
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Completed
NCT05081674 2023-10-11
BLISS
Hospital Israelita Albert Einstein
Phase 2 Completed
NCT04647110 2023-04-06
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Pfizer
Completed
NCT03271554 2022-11-18
Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea
Hoffmann-La Roche
Completed
NCT02013219 2020-04-21
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 1 Completed
NCT03155009 2020-02-10
ATALK
Hoffmann-La Roche
Phase 2 Completed
NCT02604342 2019-10-29
Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
Hoffmann-La Roche
Phase 3 Completed
NCT01801111 2018-11-02
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Hoffmann-La Roche
Phase 1/2 Completed